Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026)
Recursion Pharmaceuticals (RXRX) reported EBT of -$122.1 million for Q1 2026, up 39.74% on a YoY basis from -$87.4 million in Q1 2025, and down 12.96% quarter-over-quarter from -$108.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) EBT (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported EBT for 7 years, with the latest figure at -$122.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 39.74% year-over-year to -$122.1 million; the trailing twelve-month figure through Mar 2026 stood at -$564.4 million (up 1.9% YoY), and the FY2025 full-year result was -$644.9 million, down 38.75% from the prior year.
- EBT for Q1 2026 stood at -$122.1 million, down from -$108.1 million in the prior quarter.
- The five-year high for EBT was -$56.0 million in Q1 2022, with the low at -$202.6 million in Q1 2025.
- Historically, EBT has averaged -$106.4 million across 5 years, with a median of -$95.7 million in 2024.
- Annual changes were most pronounced in 2025 — EBT tumbled 119.9% — and 2026, when it soared 39.74%.
- Recursion Pharmaceuticals' EBT stood at -$61.0 million in 2022, then slumped by 59.16% to -$97.1 million in 2023, then slumped by 84.32% to -$178.9 million in 2024, then surged by 39.57% to -$108.1 million in 2025, then dropped by 12.96% to -$122.1 million in 2026.
- The last three EBT figures came in at -$122.1 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -122.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122.11 Mn |
| Dec 31, 2025 | -108.10 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.65 Mn |
| Dec 31, 2024 | -178.90 Mn |
| Sep 30, 2024 | -95.68 Mn |
| Jun 30, 2024 | -98.06 Mn |
| Mar 31, 2024 | -92.15 Mn |
| Dec 31, 2023 | -97.06 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -60.98 Mn |
| Sep 30, 2022 | -62.57 Mn |
| Jun 30, 2022 | -66.19 Mn |
| Mar 31, 2022 | -55.98 Mn |
| Dec 31, 2021 | -64.96 Mn |
| Sep 30, 2021 | -46.40 Mn |
| Jun 30, 2021 | -40.93 Mn |